Three Biotech Stocks Under $5 with Potential for 200% Growth

Three under-the-radar biotech stocks trading under $5, Hoth Therapeutics (NASDAQ:HOTH) and Silo Pharma (NASDAQ:SILO), offer potential for significant long-term upside. HOTH is up 98% in 2023 but down 35% from its 12-month high, while SILO is down 29% in 2023 but up 7% in the last three months. Both companies have pre-clinical candidates for high-demand markets, including oncology and obesity treatments. Analysts project a consensus price target of $4 for HOTH, a 150% upside from its current price.

Two under-the-radar biotech stocks, Hoth Therapeutics (NASDAQ: HOTH) and Silo Pharma (NASDAQ: SILO), are gaining attention for their potential in high-demand markets. Both companies have pre-clinical candidates for oncology and obesity treatments, with analysts projecting significant long-term upside.

Hoth Therapeutics has seen a mixed performance in 2023, with a 98% increase in stock price year-to-date but a 35% decline from its 12-month high. The company recently secured a key European regulatory milestone by submitting its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a Phase II trial of HT-001, a novel topical therapeutic for skin toxicities associated with Epidermal Growth Factor Receptor inhibitors (EGFRi) Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities^[1]. Pending EMA review and approval, the company expects to initiate European patient recruitment in early 2026. Analysts project a consensus price target of $4 for HOTH, a 150% upside from its current price.

Silo Pharma has experienced a more volatile performance in 2023, down 29% but up 7% in the last three months. The company has not yet reached the clinical trial stage but is developing precision-targeted drug formulations to treat obesity and associated metabolic diseases Aphaia Pharma Initiates Second Phase 2 Trial of Oral Candidate in Obesity^[2]. Aphaia Pharma, a Swiss/US-based clinical-stage biopharmaceutical company, is harnessing a similar approach with its lead oral glucose-based candidate in individuals with obesity. The company has dosed its first patient in a second Phase 2 study, building on encouraging initial results from a prior Phase 2 study.

Both HOTH and SILO offer potential for significant long-term upside, with pre-clinical candidates addressing high-demand markets. However, investors should be aware of the risks associated with early-stage biotech companies, including regulatory uncertainties and competitive pressures. As with any investment, thorough research and a long-term perspective are essential.